In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Adma Biologics Inc (NASDAQ: ADMA) closed at $16.02 down -3.67% from its previous closing price of $16.63. In other words, the price has decreased by -$3.67 from its previous closing price. On the day, 3.05 million shares were traded. ADMA stock price reached its highest trading level at $16.865 during the session, while it also had its lowest trading level at $15.98.
Ratios:
For a deeper understanding of Adma Biologics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 43.67 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 47.70. For the most recent quarter (mrq), Quick Ratio is recorded 3.26 and its Current Ratio is at 7.09. In the meantime, Its Debt-to-Equity ratio is 0.48 whereas as Long-Term Debt/Eq ratio is at 0.48.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 22 ’24 when Tade Brad L. sold 15,000 shares for $21.15 per share. The transaction valued at 317,250 led to the insider holds 199,433 shares of the business.
Grossman Adam S sold 48,967 shares of ADMA for $1,033,204 on Nov 22 ’24. The President and CEO now owns 1,989,007 shares after completing the transaction at $21.10 per share. On Nov 22 ’24, another insider, Grossman Adam S, who serves as the Director and Officer of the company, bought 48,967 shares for $21.30 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 3786967808 and an Enterprise Value of 3811648768. As of this moment, Adma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 57.98, and their Forward P/E ratio for the next fiscal year is 23.44. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.76. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.89 while its Price-to-Book (P/B) ratio in mrq is 16.33. Its current Enterprise Value per Revenue stands at 9.957 whereas that against EBITDA is 30.277.
Stock Price History:
The Beta on a monthly basis for ADMA is 0.76, which has changed by 2.0283554 over the last 52 weeks, in comparison to a change of 0.23631513 over the same period for the S&P500. Over the past 52 weeks, ADMA has reached a high of $23.64, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is -16.36%, while the 200-Day Moving Average is calculated to be 10.18%.
Shares Statistics:
For the past three months, ADMA has traded an average of 3.02M shares per day and 2559690 over the past ten days. A total of 236.38M shares are outstanding, with a floating share count of 228.50M. Insiders hold about 3.34% of the company’s shares, while institutions hold 88.75% stake in the company. Shares short for ADMA as of 1735603200 were 13622817 with a Short Ratio of 4.51, compared to 1732838400 on 12906077. Therefore, it implies a Short% of Shares Outstanding of 13622817 and a Short% of Float of 5.9299998.
